Clinical Trials

80 enrolled

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT05384821 2026-03-18

MetroWilms

Phase 1/2 Recruiting

28 enrolled

Kidney Neoplasms, Wilms Tumor

NCT07194044 2026-03-16

METTSEO

15 enrolled

Sarcoma

Sarcoma, Ewing

NCT05453500 2026-03-13

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Burkitt Lymphoma

NCT06738368 2026-03-13

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05068232 2026-03-04

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

49 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04231877 2026-03-03

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

56 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01356290 2026-02-23

MEMMAT

232 enrolled

Ependymoma, Medulloblastoma, Recurrence

NCT03136146 2026-02-17

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

42 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06528691 2026-02-17

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

52 enrolled

Glioma, Central Nervous System Neoplasms

NCT05535166 2026-02-12

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

130 enrolled

Brain Neoplasms, Medulloblastoma

NCT06528496 2026-02-10

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

45 enrolled

Neuroblastoma

NCT05762419 2026-01-28

FUS Etoposide for DMG

10 enrolled

Diffuse Intrinsic Pontine Glioma, Brain Diseases, Brain Neoplasms, Glioma, Nervous System Neoplasms, Central Nervous System Neoplasms

NCT07097363 2026-01-15

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

18 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05624996 2026-01-14

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

474 enrolled

Lung Neoplasms

NCT06039371 2026-01-14

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

69 enrolled

Prostatic Neoplasms

NCT05106296 2026-01-09

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

37 enrolled

Brain Neoplasms, Ependymoma, Glioblastoma, Medulloblastoma, Neuroectodermal Tumors, Primitive

NCT02106988 2026-01-07

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

40 enrolled

Lymphoma

NCT04699838 2026-01-02

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

NCT07141264 2025-12-30

Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy

32 enrolled

SCLC,Extensive Stage

NCT04177004 2025-12-15

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

Other hematologic neoplasm

53 enrolled

Hematologic Neoplasms

NCT04696575 2025-12-15

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

28 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT06091124 2025-12-08

NEOBLAST

22 enrolled

Urinary Bladder Neoplasms

NCT04871607 2025-12-04

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

33 enrolled

Hodgkin Disease

NCT04681417 2025-11-28

RETINO 2018

Phase 2/3 Recruiting

225 enrolled

Other solid neoplasm

Retinoblastoma

NCT06937866 2025-11-21

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

Phase 1/2 Recruiting

38 enrolled

Neoplasms, Germ Cell and Embryonal

NCT05821088 2025-11-20

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

37 enrolled

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07232134 2025-11-20

AML-DS-2025

Other hematologic neoplasm

100 enrolled

Down Syndrome, Leukemia, Myeloid, Acute

NCT07059975 2025-11-04

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Phase EARLY_PHASE1 Recruiting

36 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07002216 2025-11-03

BrECADD

48 enrolled

Hodgkin Disease

NCT02605421 2025-10-21

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

12 enrolled

Neuroblastoma

NCT04679012 2025-10-07

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07199296 2025-09-30

Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment

45 enrolled

Lymphoma, Mantle-Cell

NCT06838208 2025-09-24

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

56 enrolled

Small Cell Lung Carcinoma

NCT06144736 2025-09-15

PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND

60 enrolled

Seminoma

NCT07081022 2025-08-21

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

180 enrolled

Lymphoma, B-Cell

NCT02393157 2025-08-08

O-ICE

25 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04268121 2025-07-23

NEONEC

EndocrineGastrointestinal

78 enrolled

Gastrointestinal Neoplasms, Carcinoma, Neuroendocrine

NCT05312671 2025-06-29

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

63 enrolled

Urinary Bladder Neoplasms

NCT04765098 2025-06-26

Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

60 enrolled

Glioblastoma

NCT05253495 2025-06-13

RADICAL

80 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT07008716 2025-06-06

Omitting CTV for Primary Tumor in LS-SCLC

852 enrolled

Radiation Injuries, Disease Progression

NCT05294055 2025-05-13

Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

120 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT04804007 2025-04-18

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

64 enrolled

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal

NCT06483282 2025-04-15

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

38 enrolled

Small Cell Lung Cancer Limited Stage

NCT03669783 2025-04-08

RANDOMET

110 enrolled

Childhood Renal Tumor

NCT03643276 2025-04-06

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

5,000 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05800587 2025-04-04

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

280 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT06911606 2025-04-04

Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)

45 enrolled

SCLC, Limited Stage

NCT06249191 2025-03-24

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Phase 1/2 Recruiting